Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Theratechnologies Inc > TH-1902 pause is no reason to blame management
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(14)
•••
Comment by LouisWon Dec 08, 2022 11:04am
108 Views
Post# 35159107

RE:RE:RE:RE:RE:TH-1902 pause is no reason to blame management

RE:RE:RE:RE:RE:TH-1902 pause is no reason to blame managementMaybe SN38 is doable? I guess they already have some data.

jfm1330 wrote:
TH1902 TH19P01

PDC Aeterna Zentaris PDCAEZS-108 Zoptrex PDC Thera Ib  

TH1902 TH19P01 “”

PDC PDC ADC Lutathera PluvictoLu177-Dotatate Lu177-PSMA Lu177 DOTA Pluvicto

“”Thera TH19P01 DOTA TH19P01 Lu177 Ga68 Ga68 “” Ga68 Lu177 I

Ga68 Lu177 Lu177

TH19P01 DOTA-Lu177 DOTA-Ga68 ADC

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities